These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35863683)

  • 1. Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B.
    Choi HSJ; Hirode G; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong GLH; Brakenhoff SM; Chien RN; Feld JJ; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1513-1522.e4. PubMed ID: 35863683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B.
    Chen CH; Peng CY; Hu TH; Wang JH; Hung CH; Lu SN
    Aliment Pharmacol Ther; 2023 Aug; 58(3):334-345. PubMed ID: 37265196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.
    Kuo MT; Hu TH; Hung CH; Wang JH; Lu SN; Tsai KL; Chen CH
    Aliment Pharmacol Ther; 2019 Jan; 49(2):218-228. PubMed ID: 30484881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
    Papatheodoridis GV; Rigopoulou EI; Papatheodoridi M; Zachou K; Xourafas V; Gatselis N; Hadziyannis E; Vlachogiannakos J; Manolakopoulos S; Dalekos GN
    Antivir Ther; 2018; 23(8):677-685. PubMed ID: 30044765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort.
    Hsu YC; Jun DW; Peng CY; Yeh ML; Trinh H; Wong GL; Kim SE; Chen CH; Oh H; Lin CH; Trinh L; Wong VW; Yoon E; Ahn SB; Huang D; Cho YK; Jeong JY; Jeong SW; Kim HS; Xie Q; Liu L; Riveiro-Barciela M; Tsai PC; Accarino EV; Toyoda H; Enomoto M; Preda C; Marciano S; Hoang J; Huang CF; Kozuka R; Yasuda S; Istratescu D; Lee DH; Su JY; Huang YT; Huang JF; Dai CY; Chuang WL; Yuen MF; Gadano A; Cheung R; Lim SG; Buti M; Yu ML; Nguyen MH
    Hepatol Int; 2022 Dec; 16(6):1297-1307. PubMed ID: 36070123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
    Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
    J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir.
    Fang HW; Yen YH; Hung CH; Wang JH; Hu TH; Lu SN; Chen CH
    Dig Dis Sci; 2022 Jul; 67(7):3402-3411. PubMed ID: 34241753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
    Hall SAL; Vogrin S; Wawryk O; Burns GS; Visvanathan K; Sundararajan V; Thompson A
    Gut; 2022 Aug; 71(8):1629-1641. PubMed ID: 34493592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
    J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy.
    Su TH; Yang HC; Tseng TC; Liou JM; Liu CH; Chen CL; Chen PJ; Chen DS; Liu CJ; Kao JH
    J Infect Dis; 2018 Mar; 217(8):1193-1201. PubMed ID: 29300980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen-Positive Chronic Hepatitis B.
    Behera MK; Pati GK; Narayan J; Mishra D; Meher LK; Singh A; Uthansingh K; Sahu MK
    J Clin Exp Hepatol; 2021; 11(1):37-44. PubMed ID: 33679047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy.
    Lin MJ; Su TH; Liu CJ; Yang HC; Chen CL; Liou JM; Tseng TC; Liu CH; Hong CM; Chen PJ; Kao JH
    J Formos Med Assoc; 2023 Jul; 122(7):564-573. PubMed ID: 36872131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study.
    Peng CW; Jeng WJ; Yang HI; Liu YC; Chien RN; Liaw YF
    J Gastroenterol Hepatol; 2022 Nov; 37(11):2164-2172. PubMed ID: 35869752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
    Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
    Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
    Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
    Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
    Chiu SM; Kuo YH; Wang JH; Hung CH; Hu TH; Lu SN; Chen CH
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2989-2997.e3. PubMed ID: 32353534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
    Wang YH; Liao J; Zhang DM; Wu DB; Tao YC; Wang ML; Chen EQ; Tang H
    J Med Virol; 2020 Mar; 92(3):302-308. PubMed ID: 31609007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.